Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance

[1]  Chun-Ka Wong,et al.  Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications , 2023, Biomedicines.

[2]  G. Calin,et al.  Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis , 2022, Science Translational Medicine.

[3]  C. Blank,et al.  Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma. , 2022, JAMA oncology.

[4]  M. Donia,et al.  Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor‐induced colitis , 2022, Alimentary pharmacology & therapeutics.

[5]  P. Vilmann,et al.  COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis , 2022, Journal for ImmunoTherapy of Cancer.

[6]  J. Soria,et al.  Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. , 2022, Cancer treatment reviews.

[7]  Mark M. Davis,et al.  Standing on the shoulders of mice. , 2022, Immunity.

[8]  Y. Wang,et al.  Blockade of IL-6 inhibits tumor immune evasion and improves anti-PD-1 immunotherapy. , 2022, Cytokine.

[9]  Yukio Fujiwara,et al.  Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Regev,et al.  Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy , 2022, Cell.

[11]  M. Oldstone,et al.  Myeloid reprogramming by JAK inhibition enhances checkpoint blockade therapy , 2022, bioRxiv.

[12]  Y. Belkaid,et al.  Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[13]  K. Shannon,et al.  Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial , 2022, Nature Medicine.

[14]  N. Sun,et al.  Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer , 2022, BMC Medicine.

[15]  J. Wargo,et al.  Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. , 2022, Cancer cell.

[16]  Shikai Liu,et al.  Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway , 2022, Bioengineered.

[17]  F. Ghiringhelli,et al.  Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era , 2022, Cells.

[18]  Y. Imai,et al.  Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy , 2022, Cancers.

[19]  H. Duan,et al.  The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8+ T cells in bladder cancer , 2022, Medical Oncology.

[20]  Douglas B. Johnson,et al.  Harnessing big data to characterize immune-related adverse events , 2022, Nature Reviews Clinical Oncology.

[21]  J. Heron,et al.  Exploring the causal role of intimate partner violence and abuse on depressive symptoms in young adults: a population-based cohort study , 2022, BMC Medicine.

[22]  W. Miller,et al.  Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition , 2022, Journal for ImmunoTherapy of Cancer.

[23]  Xin Zhao,et al.  Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor , 2021, Frontiers in Immunology.

[24]  D. Schadendorf,et al.  Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. McQuade,et al.  Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study , 2021, Journal for ImmunoTherapy of Cancer.

[26]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Cohen,et al.  The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response , 2021, Frontiers in Cell and Developmental Biology.

[28]  F. Mazzoni,et al.  Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis , 2021, Molecules.

[29]  R. Dummer,et al.  Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. , 2021, European journal of cancer.

[30]  Theresa L. Walunas,et al.  Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR , 2021, Journal for ImmunoTherapy of Cancer.

[31]  R. Sullivan,et al.  1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma , 2021, Annals of Oncology.

[32]  A. Tomelleri,et al.  Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. , 2021, European journal of internal medicine.

[33]  R. Sullivan,et al.  Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy , 2021, Clinical Cancer Research.

[34]  Xudong Yin,et al.  Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment. , 2021, International immunopharmacology.

[35]  C. Goyvaerts,et al.  TNFα and Immune Checkpoint Inhibition: Friend or Foe for Lung Cancer? , 2021, International journal of molecular sciences.

[36]  Kunihiko Kobayashi,et al.  Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs , 2021, Journal of clinical medicine.

[37]  B. Salomon.  Insights into the biology and therapeutic implications of TNF and regulatory T cells , 2021, Nature Reviews Rheumatology.

[38]  Bhavisha P. Sheth,et al.  Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab , 2021, Journal for ImmunoTherapy of Cancer.

[39]  C. Rudd,et al.  Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy , 2021, PloS one.

[40]  Yingyan Yu,et al.  Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways , 2021, Oncogene.

[41]  Kazuhiko Yoshida,et al.  Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study , 2021, Targeted Oncology.

[42]  A. Bass,et al.  Reply to: TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out , 2021, Nature Reviews Rheumatology.

[43]  K. Suijkerbuijk,et al.  TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out , 2021, Nature Reviews Rheumatology.

[44]  R. Dummer,et al.  Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis , 2021, Cancers.

[45]  P. Ascierto,et al.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events , 2021, Journal for ImmunoTherapy of Cancer.

[46]  D. Hogg,et al.  Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events , 2021, Current oncology.

[47]  Hui Guo,et al.  Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non-Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis. , 2021, Clinical lung cancer.

[48]  F. Hodi,et al.  Effect of corticosteroid dosing on outcomes in high‐grade immune checkpoint inhibitor hepatitis , 2021, Hepatology.

[49]  S. Dalle,et al.  Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes , 2021, Cancers.

[50]  V. Sondak,et al.  Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis , 2021, Journal for ImmunoTherapy of Cancer.

[51]  Zhuoli Zhang,et al.  Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis , 2021, Frontiers in Oncology.

[52]  J. Wolchok,et al.  TNF in the era of immune checkpoint inhibitors: friend or foe? , 2021, Nature Reviews Rheumatology.

[53]  Xianhe Xie,et al.  Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors , 2021, Cancer Immunology, Immunotherapy.

[54]  S. Liabeuf,et al.  Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation , 2021, Therapeutic advances in medical oncology.

[55]  S. Friesland,et al.  Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. , 2021, European journal of cancer.

[56]  T. Greten,et al.  Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models , 2020, iScience.

[57]  R. Dummer,et al.  Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma , 2020, European journal of cancer.

[58]  N. Ajami,et al.  Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade , 2020, Nature Medicine.

[59]  N. Meyer,et al.  Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial , 2020, Clinical Cancer Research.

[60]  P. Sorger,et al.  Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma , 2020, Clinical Cancer Research.

[61]  F. Massari,et al.  Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. , 2020, Immunotherapy.

[62]  F. Scotté,et al.  How to manage patients with corticosteroids in oncology in the era of immunotherapy? , 2020, European journal of cancer.

[63]  R. Scolyer,et al.  Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab , 2020, Journal for ImmunoTherapy of Cancer.

[64]  K. Reynolds,et al.  Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor-induced gastroenterocolitis. , 2020, European journal of cancer.

[65]  C. Paweletz,et al.  Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC , 2020, Journal for ImmunoTherapy of Cancer.

[66]  J. Yearley,et al.  Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions , 2020, Journal for ImmunoTherapy of Cancer.

[67]  A. Regev,et al.  Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment. , 2020, Immunity.

[68]  I. Gich,et al.  Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents , 2020, Frontiers in Oncology.

[69]  E. Wherry,et al.  PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma , 2020, JCI insight.

[70]  V. Paradis,et al.  Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal. , 2020, Clinics and research in hepatology and gastroenterology.

[71]  J. Larkin,et al.  Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma , 2020, ESMO Open.

[72]  M. Merl,et al.  The impact of corticosteroid use during anti-PD1 treatment , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[73]  E. Shin,et al.  Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors , 2020, Immune network.

[74]  C. Porta,et al.  Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. , 2020, Clinical genitourinary cancer.

[75]  A. Imagawa,et al.  Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice. , 2020, International journal of cardiology.

[76]  M. Hudson,et al.  Moving towards personalized treatments of immune-related adverse events , 2020, Nature Reviews Clinical Oncology.

[77]  M. Brown,et al.  Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune‐related adverse events after immune checkpoint inhibitor therapy , 2020, Asia-Pacific journal of clinical oncology.

[78]  I. Svane,et al.  Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors. , 2020, European journal of cancer.

[79]  F. Petrelli,et al.  Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis , 2020, Cancers.

[80]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[81]  C. Blank,et al.  Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry , 2020, Clinical Cancer Research.

[82]  D. Schadendorf,et al.  Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo , 2020, JAMA oncology.

[83]  Douglas B. Johnson,et al.  Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[84]  T. Okazaki,et al.  Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells , 2019, The Journal of Biological Chemistry.

[85]  J. Wolchok,et al.  Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids , 2019, The Journal of experimental medicine.

[86]  R. Saito,et al.  Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology , 2019, International Journal of Clinical Oncology.

[87]  J. Badger,et al.  Laboratory mice born to wild mice have natural microbiota and model human immune responses , 2019, Science.

[88]  L. Boon,et al.  Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment , 2019, Oncoimmunology.

[89]  Xin Wang,et al.  Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. , 2019, JAMA oncology.

[90]  R. Dummer,et al.  Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[91]  K. Shannon,et al.  Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. , 2019, The Lancet. Oncology.

[92]  U. Stierner,et al.  Real-world data on PD-1 inhibitor therapy in metastatic melanoma , 2019, Acta oncologica.

[93]  K. Goldberg,et al.  Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  B. Dréno,et al.  Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey. , 2019, Journal of immunotherapy.

[95]  I. Melero,et al.  Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy , 2019, Nature.

[96]  Toshio Tanaka,et al.  Targeting Interleukin-6 Signaling in Clinic. , 2019, Immunity.

[97]  A. Jazaeri,et al.  Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis , 2019, Journal of Immunotherapy for Cancer.

[98]  Wen-Chien Huang,et al.  Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity—From Case Report to Mouse Model Validation , 2019, Cancers.

[99]  N. Sharma,et al.  Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade , 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[100]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[101]  A. Charabaty,et al.  Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study , 2018, Journal of Immunotherapy for Cancer.

[102]  R. Amaria,et al.  Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis , 2018, Journal of Immunotherapy for Cancer.

[103]  Christopher M. Jackson,et al.  Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system , 2018, Oncoimmunology.

[104]  Xiaofei Yan,et al.  Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[105]  R. Sullivan,et al.  High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma , 2018, Cancer.

[106]  S. Senju,et al.  Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. , 2018, Cancer research.

[107]  Deric M. Park,et al.  Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy , 2018, Journal of Immunotherapy for Cancer.

[108]  Amy M Sion,et al.  Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy. , 2018, Seminars in oncology.

[109]  G. Raju,et al.  Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson , 2018, Journal of Immunotherapy for Cancer.

[110]  O. Delpuech,et al.  Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity , 2018, Oncoimmunology.

[111]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[112]  D. Sansom,et al.  CTLA-4: a moving target in immunotherapy. , 2018, Blood.

[113]  P. Rochaix,et al.  TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma , 2017, Nature Communications.

[114]  S. Senju,et al.  Immune‐suppressive effects of interleukin‐6 on T‐cell‐mediated anti‐tumor immunity , 2017, Cancer science.

[115]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[116]  K. Ikeo,et al.  Lack of interleukin‐6 in the tumor microenvironment augments type‐1 immunity and increases the efficacy of cancer immunotherapy , 2017, Cancer science.

[117]  D. Schadendorf,et al.  Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[119]  Jun Shen,et al.  IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model. , 2017, Biochemical and biophysical research communications.

[120]  C. Weber,et al.  Neutrophils as protagonists and targets in chronic inflammation , 2017 .

[121]  Kebin Liu,et al.  JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer , 2017, Oncoimmunology.

[122]  T. Graeber,et al.  Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. , 2017, Cancer discovery.

[123]  H. Ishwaran,et al.  Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade , 2016, Cell.

[124]  Michael C. Ostrowski,et al.  IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer , 2016, Gut.

[125]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[126]  A. Bhatt,et al.  Role of interleukin-6 in cancer progression and therapeutic resistance , 2016, Tumor Biology.

[127]  G. Thomas,et al.  Infliximab for IPILIMUMAB-Related Colitis—Letter , 2015, Clinical Cancer Research.

[128]  J. Wolchok,et al.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  Ping Zhang,et al.  Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy , 2015, BMC Immunology.

[130]  J. Sosman,et al.  Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center , 2015, Cancer Immunology Research.

[131]  A. Giobbie-Hurder,et al.  Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study , 2014, Clinical Cancer Research.

[132]  Jing Liu,et al.  Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies , 2014, Clinical & translational immunology.

[133]  C. Riccardi,et al.  GILZ promotes production of peripherally induced Treg cells and mediates the crosstalk between glucocorticoids and TGF-β signaling. , 2014, Cell reports.

[134]  A. Giobbie-Hurder,et al.  Challenges of guarantee-time bias. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  A. Maraveyas,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma , 2009, Clinical Cancer Research.

[136]  C. Sturgeon,et al.  A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[137]  M. Gore,et al.  Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  T. Ganesan,et al.  Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  A. Harris,et al.  A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[140]  T. Fleming,et al.  A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[141]  F. Herrmann,et al.  Phase I trial of recombinant human tumour necrosis factor α in patients with advanced malignancy , 1991 .

[142]  D. Newell,et al.  In pursuit of evidence based integrated care , 1987, British Journal of Cancer.

[143]  M. Rosenblum,et al.  Phase I study of recombinant tumor necrosis factor in cancer patients. , 1987, Cancer research.

[144]  G. Coukos,et al.  New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. , 2019, The Lancet. Oncology.

[145]  P. Tyre.  Combination therapy. , 2004, Newsweek.